The effect of demlatonin on the treatment of sleep disorders in hemodialysis patients

Comparision the effect of 3 & 6 mg melatonin on the treatment of sleep disorders in patients undergoing hemodialysis; Randomised clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220112053698N1

Enrollment

Registered

2022-06-12

Start date

2022-02-21

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESRD. Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease

Interventions

Intervention 1: Intervention group 1: Melatonin: 3 mg daily orally for 3 months. Intervention 2: Intervention group 2: Melatonin: 6 mg daily orally for 3 months. Intervention 3: Control group: placebo

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Complete consent to participate in this study Patients with ESRD with a history of at least 3 months of dialysis (3 times a week for 4 hours) Age 16 years and older

Exclusion criteria

Exclusion criteria: STOP-BANG = 3 values that are in favor of the possibility of obstructive sleep apnea. Diagnosed with neurological disorders People with craniofacial disorders and neurological defects, whether acquired or congenital Addiction or regular use of sleeping pills Taking anticoagulants and anticonvulsants

Design outcomes

Primary

Measure	Time frame
Sleep quality. Timepoint: Before and after study. Method of measurement: Standard sleep quality questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNina Kamali

Qazvin University of Medical Sciences

mrhamed2009@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026